No Data
No Data
H.C. Wainwright Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $1
Express News | HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
Lyell Immunopharma Analyst Ratings
Express News | Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation For LYL314 In Treatment Of Relapsed And/Or Refractory Large B-Cell Lymphoma
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed And/or Refractory Large B-Cell Lymphoma
Director's Bold Move: Major Stock Purchase in Lyell Immunopharma!